Japan Trading & Investment Conglomerate Mitsui & Rohto Pharmaceutical Buy 86% of Singapore-Based Traditional Chinese Medicine Group Eu Yan Sang Intern
Eu Yan Sang Caproasia.com | The leading source of data, research, information & resource for financial professionals, investment managers, professional investors, family offices & advisors to institutions, billionaires, UHNWs & HNWs. Covering capital markets, investments and private wealth in Asia. How do you invest $3 million to $300 million? How do you manage $20 million to $3 billion of assets? Caproasia - Learn more Caproasia Access | Events | Summits | Register Events | The Financial Centre The 2024 Investment Day | 2024 Family Office Summits | Family Office Circle This site is for accredited investors, professional investors, investment managers and financial professionals only. You should have assets around $3 million to $300 million or managing $20 million to $3 billion. 
Japan Trading & Investment Conglomerate Mitsui & Rohto Pharmaceutical Buy 86% of Singapore-Based Traditional Chinese Medicine Group Eu Yan Sang International at $593 Million Valuation from Righteous Crane Holding & Takeover Bid of Remaining 14% Shares, EYS Founding Family Will Reinvest Partially in New Group with 10% Shareholding, Mitsui Owns 30% & Rohto Pharmaceutical Owns 60% 5th April 2024 | Hong Kong
Japan trading & investment conglomerate Mitsui (Mitsui & Co.) & Japan Rohto Pharmaceutical have partner to buy 86% of Singapore-based traditional Chinese medicine group Eu Yan Sang International (EYS) at $593 million valuation (S$800 million) from Righteous Crane Holding (Eu Family, Tower Capital Asia & Temasek Holdings), and a takeover bid of the remaining 14% shares. EYS founding family will reinvest partially in the new group (special purpose vehicle) with 10% shareholding, Mitsui owns 30% & Rohto Pharmaceutical owns 60%. Mitsui: “Mitsui & Co., Ltd. (“Mitsui”, Head Office: Tokyo, President and CEO: Kenichi Hori) has decided to acquire shares in Eu Yan Sang International Ltd (“EYS”, Head Office: Singapore) jointly with ROHTO Pharmaceutical Co., Ltd. (“ROHTO”, Head Office: Ikuno-ku, Osaka, President and CEO: Masashi Sugimoto) and others. Based in Singapore, EYS manufactures and sells traditional Chinese medicines. A special purpose company (“SPC”), that is established in Singapore and will be jointly owned by Mitsui and Rohto, will acquire approximately 86% of the EYS shares from Righteous Crane Holding Pte. Ltd. (“RCH”, Head Office: Singapore), pursuant to a conditional sale and purchase agreement (“SPA”). Upon fulfillment of the condition in the SPA, a takeover bid for the remaining 14% of EYS shares will be executed and the founding family of EYS will reinvest partially into the SPC (as part of management retention arrangements). Mitsui invested in EYS through a fund in November 2022 as an indirect investor. The existing interest in EYS through its fund holdings will cease as a result of RCH’s sale of the EYS shares, and Mitsui will re-invest in EYS through the SPC, utilizing the proceeds from the above-mentioned sale. If the SPC is able to acquire 100% of the EYS shares from RCH and under the takeover bid, Mitsui will own approximately 30% effective interest in EYS shares, ROHTO approximately 60%, and the founding family approximately 10%. The acquisition of 100% of EYS shares is valued at approximately SGD800 million (approximately ¥88 billion), subject to adjustments. Mitsui will acquire shares worth an estimated ¥15 billion on a net basis, excluding the proceeds from the RCH’s sale of the EYS shares. Completion of the acquisition is targeted to take place on or around 30 June 2024.” EYS Profile – Eu Yan Sang, founded in 1879, is a leading integrative health and wellness company with a unique heritage in Traditional Chinese Medicine (“TCM”) that operates over 170 retail outlets and 30 clinics in its core Singapore, Hong Kong, and Malaysia markets. Eu Yan Sang also has a significant network across 29 markets, including manufacturing capabilities in Malaysia and Hong Kong. Through its comprehensive and modern product portfolio, combined with a strong emphasis on continuous product innovation, Eu Yan Sang seeks to empower customers to live their best quality of life by providing health and wellness solutions rooted in TCM wisdom.
“ Japan Trading & Investment Conglomerate Mitsui & Rohto Pharmaceutical Buy 86% of Singapore-Based Traditional Chinese Medicine Group Eu Yan Sang International at $593 Million Valuation from Righteous Crane Holding & Takeover Bid of Remaining 14% Shares, EYS Founding Family Will Reinvest Partially in New Group with 10% Shareholding, Mitsui Owns 30% & Rohto Pharmaceutical Owns 60% “
- Article continues below - Quick Links, Ads & Announcements Caproasia Access | Events | Summits | Register Events | The Financial Centre The 2024 Investment Day | 2024 Family Office Summits | Family Office Circle Sign Up Basic Member: $5 Monthly | $60 Yearly Newsletter Daily 2 pm (Promo): $20 Monthly | $180 Yearly (FP: $680) The 2024 Investment Day 6th March Hong Kong | 13th March Singapore Private Equity, Hedge Funds, Boutique Funds, Private Markets & more. Taking place on 6th March 2024 in Hong Kong, 13th March 2024 in Singapore. Visit | Register here The 2024 Family Office Summit10th April Hong Kong | 24th April Singapore Join 100+ single family offices & family office professionals in Hong Kong & Singapore Links: 2024 Family Office Summit | Register here
Japan Trading & Investment Conglomerate Mitsui & Rohto Pharmaceutical Buy 86% of Singapore-Based Traditional Chinese Medicine Group Eu Yan Sang International at $593 Million Valuation from Righteous Crane Holding & Takeover Bid of Remaining 14% Shares, EYS Founding Family Will Reinvest Partially in New Group with 10% Shareholding, Mitsui Owns 30% & Rohto Pharmaceutical Owns 60%
Eu Yan Sang 4th April 2024 – Mitsui & Co., Ltd. (“Mitsui”, Head Office: Tokyo, President and CEO: Kenichi Hori) has decided to acquire shares in Eu Yan Sang International Ltd (“EYS”, Head Office: Singapore) jointly with ROHTO Pharmaceutical Co., Ltd. (“ROHTO”, Head Office: Ikuno-ku, Osaka, President and CEO: Masashi Sugimoto) and others. Based in Singapore, EYS manufactures and sells traditional Chinese medicines.
A special purpose company (“SPC”), that is established in Singapore and will be jointly owned by Mitsui and Rohto, will acquire approximately 86% of the EYS shares from Righteous Crane Holding Pte. Ltd. (“RCH”, Head Office: Singapore), pursuant to a conditional sale and purchase agreement (“SPA”). Upon fulfillment of the condition in the SPA, a takeover bid for the remaining 14% of EYS shares will be executed and the founding family of EYS will reinvest partially into the SPC (as part of management retention arrangements). Mitsui invested in EYS through a fund in November 2022 as an indirect investor. The existing interest in EYS through its fund holdings will cease as a result of RCH’s sale of the EYS shares, and Mitsui will re-invest in EYS through the SPC, utilizing the proceeds from the above-mentioned sale. If the SPC is able to acquire 100% of the EYS shares from RCH and under the takeover bid, Mitsui will own approximately 30% effective interest in EYS shares, ROHTO approximately 60%, and the founding family approximately 10%. The acquisition of 100% of EYS shares is valued at approximately SGD800 million (approximately ¥88 billion), subject to adjustments. Mitsui will acquire shares worth an estimated ¥15 billion on a net basis, excluding the proceeds from the RCH’s sale of the EYS shares. Completion of the acquisition is targeted to take place on or around 30 June 2024.
Eu Yan Sang, founded in 1879, is a leading integrative health and wellness company with a unique heritage in Traditional Chinese Medicine (“TCM”) that operates over 170 retail outlets and 30 clinics in its core Singapore, Hong Kong, and Malaysia markets. Eu Yan Sang also has a significant network across 29 markets, including manufacturing capabilities in Malaysia and Hong Kong. Through its comprehensive and modern product portfolio, combined with a strong emphasis on continuous product innovation, Eu Yan Sang seeks to empower customers to live their best quality of life by providing health and wellness solutions rooted in TCM wisdom.
In 2018, Mitsui invested in Thorne HealthTech Inc., an American manufacturer and supplier of advanced functional supplements. Since then, Mitsui has worked to build a science-based, individualized solutions business for pre-symptomatic conditions. Mitsui invested in EYS through the fund and has since contributed to the expansion of EYS’ business by helping to enhance the value of the EYS brand and supporting the company’s overseas expansion. Through these activities, Mitsui reconfirmed EYS’s strong business potential and how Mitsui could contribute to its business expansion, which led to Mitsui’s decision to re-invest in EYS with ROHTO and the founding family through the SPC. Leveraging the competitiveness of EYS’ brand and products in Asia and ROHTO’s R&D and marketing capabilities, Mitsui will work to create an innovative new business.
Mitsui has identified “Wellness Ecosystem Creation” as one of its key strategic initiatives in the Medium-term Management Plan 2026. Through the provision of healthcare, preventive care, and solutions for pre-symptomatic conditions, as well as the supply of foods that offer health benefits, Mitsui will contribute to the qualitative enhancement of today’s increasingly diverse consumer lifestyles. Mitsui will continue to support the realization of richer and brighter lives by enhancing health and well-being through its contributions in the area of preventive care and solutions for pre-symptomatic conditions.
ROHTO’s corporate purpose is to lead all individuals and society to a state of well-being by delivering health to people around the world through its products and services. The development of its business in line with this purpose is guided by its business domain vision 2030, which calls for further expansion and reinforcement of its core business activities in the areas of OTC pharmaceuticals, skincare products, and other food items.
Managing $20 million to $3 billion. Investing $3 million to $300 million. For Investment Managers, Hedge Funds, Boutique Funds, Private Equity, Venture Capital, Professional Investors, Family Offices, Private Bankers & Advisors, sign up today. Subscribe to Caproasia and receive the latest news, data, insights & reports, events & programs daily at 2 pm. Join Events & Find Services Join Investments, Private Wealth, Family Office events in Hong Kong, Singapore, Asia-wide. Find hard-to-find $3 million to $300 million financial & investment services at The Financial Centre | TFC. Find financial, investment, private wealth, family office, real estate, luxury investments, citizenship, law firms & more. List hard-to-find financial & private wealth services. Have a product launch? Promote a product or service? List your service at The Financial Centre | TFC. Join interviews & editorial and be featured on Caproasia.com or join Investments, Private Wealth, Family Office events. Contact us at [email protected] or [email protected] Caproasia.com | The leading source of data, research, information & resource for financial professionals, investment managers, professional investors, family offices & advisors to institutions, billionaires, UHNWs & HNWs. Covering capital markets, investments and private wealth in Asia. How do you invest $3 million to $300 million? How do you manage $20 million to $3 billion of assets? Quick Links Caproasia Access | Events | Summits | Register Events | The Financial Centre The 2024 Investment Day | 2024 Family Office Summits | Family Office Circle 2021 Data Release 2020 List of Private Banks in Hong Kong2020 List of Private Banks in Singapore 2020 Top 10 Largest Family Office2020 Top 10 Largest Multi-Family Offices2020 Report: Hong Kong Private Banks & Asset Mgmt - $4.49 Trillion2020 Report: Singapore Asset Mgmt - $3.48 Trillion AUM For Investors | Professionals | Executives Latest data, reports, insights, news, events & programs Everyday at 2 pm Direct to your inbox Save 2 to 8 hours per week. Organised for success Register Below For CEOs, Heads, Senior Management, Market Heads, Desk Heads, Financial Professionals, Investment Managers, Asset Managers, Fund Managers, Hedge Funds, Boutique Funds, Analysts, Advisors, Wealth Managers, Private Bankers, Family Offices, Investment Bankers, Private Equity, Institutional Investors, Professional Investors Get Ahead in 60 Seconds. Join 10,000 + Save 2 to 8 hours weekly. Organised for Success. Sign Up / Register You are:
InvestorProfessionalFamily OfficeExecutive
Select:
SubscriptionMembershipEvents
Interests / Events / Summits / Roundtables / Networking:
Professional InvestorPrivate WealthFamily OfficePrivate BankingWealth ManagementInvestmentsAlternativesPrivate MarketsCapital MarketsESG & SICEO & EntrepreneursTax, Legal & RisksHNW & UHNWs Insights
Your Name*
Company*
Job Title*
Email 1 (Work / Personal)*
Email 2 (Work / Personal)
Country
New to Caproasia Learn More | Sign Up | Subscribe | Register Events Caproasia Users - Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
- Professional Investor
- Family Office
- HNW Partnership
- Family Office Circle
- Family Office Networking
- Family Office Roundtable
- The Family Office Summit
- March 2024 - Hong Kong
- March 2024 - Singapore
- June 2024 - Hong Kong
- June 2024 - Singapore
- Sept 2024 - Hong Kong
- Sept 2024 - Singapore
- Visit: The Investment Day | Register: Click here
- The Investment Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
Owl Media Group takes pride in providing social-first platforms which equally benefit and facilitate engagement between businesses and consumers and creating much-needed balance to make conducting business, easier, safer, faster and better. The vision behind every platform in the Owl Media suite is to make lives better and foster a healthy environment in which parties can conduct business efficiently. Facilitating free and fair business relationships is crucial for any thriving economy and Owl Media bridges the gap and open doors for transparent and successful transacting. No advertising funds influence the functionality of our media platforms because we value authenticity and never compromise on quality no matter how lucrative the offers from advertisers may seem.